ANIX - Company ID 0000715446
Anixa Biosciences Inc trades as ANIX. This page tracks Anixa Biosciences Inc through 960 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Over the last 11 fiscal years Anixa Biosciences Inc's revenue declined from $388.85K to $210.00K, a compound annual decline rate of 5.4%. Net profit margin compressed from -1672.1% to -5978.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-03-11 |
| Quarterly report | 10-Q | 2026-03-09 |
| Major company event | 8-K | 2026-02-09 |
| Insider trade | 4 | 2026-01-29 |
| Proxy statement | DEF 14A | 2026-01-28 |
| Employee stock plan | S-8 | 2026-01-12 |
| Annual report | 10-K | 2026-01-12 |
| SCHEDULE 13D/A | - | 2026-01-06 |
The largest companies sharing Anixa Biosciences Inc's SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Anixa Biosciences Inc reported a net loss of $10.93M.